Physician profile
Peter Andrade
NPI 1417287707
$6,429.74
in general payments reported to CMS, 2019-2025
12 companies · $62.54 in 2025
The $62.54 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $348 · 2022: $690 · 2023: $1,575 · 2024: $3,293 · 2025: $62.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $3,944 · Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $3,944.07 |
| Food and Beverage | $986.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $3,944.07 | 2023-2024 | |
| Axogen | $682.04 | 2019-2025 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector |
| Integra Lifesciences Corporation | $607.90 | 2020-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Innovation Technologies INC | $427.48 | 2024 | Irrisept |
| Allergan, INC. | $413.31 | 2019 | |
| Stryker Corporation | $157.57 | 2022 | |
| Kerecis Limited | $115.63 | 2020-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mentor Worldwide LLC | $26.63 | 2019 | |
| Braintree Laboratories, INC. | $18.57 | 2020 | |
| Tela Bio, INC. | $18.17 | 2024 | Ovitex 2s |
| Kowa Pharmaceuticals America, INC. | $16.39 | 2025 | Zoryve |
| Electronic Waveform Lab, INC. | $1.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.